Systematic Assessment of Mycobacterium avium Subspecies Paratuberculosis Infections from 1911–2019: A Growth Analysis of Association with Human Autoimmune Diseases

Abstract

Mycobacterium avium subsp. paratuberculosis (MAP) is an understudied pathogen worldwide with continuous implications in human autoimmune diseases (ADs). The awareness of MAP appears to be low in many places and its research is at infant stage in many countries. The lack of worldwide coverage of the MAP research landscape calls for urgent research attention and prioritization. This present study aimed to assess MAP global research productivity with an emphasis on its implications in ADs via bibliometric and growth analytic frameworks from authors, countries, institutions, international, disciplines and collaboration network perspectives. MAP primary articles were retrieved from the Scopus database and the Web of Science from 1911 to 2019 via title-specific algorithm. Analytic results of dataset yielded a total of 3889 articles from 581 journals and 20.65 average citations per documents. The annual growth rate of MAP research for the period was 6.31%. Based on a country’s productivity (articles (%), freq. of publication (%)), the USA (887 (22.81%), 26.72%), and Australia (236 (6.07%), 6.07%) ranked the top 2 countries but Egypt and Germany had the highest average growth rate (AGR, 170%) in the last 3 years. MAP studies are generally limited to Europe, Australia, Asia, South America and few nations in Africa. It had positive growth rate (30%–100%) in relation to type 1 diabetes mellitus and rheumatoid arthritis ADs; food science and technology, immunology, agriculture, pathology, and research and experimental medicine, wildlife, environments, virulence, disease resistance, meat and meat products, osteopontin, waste milk and slurry/sludge digestion subjects; but negative growth (−130% to −30%) in ulcerative colitis and Parkinson’s disease and no growth in multiple sclerosis, sarcoidosis, thyroid disorders, psoriasis, and lupus. The mapping revealed a gross lack of collaboration networking in terms of authorship, (intra- and inter-) nationally and institutionally with a generalized collaboration index of 1.82. In conclusion, inadequate resources-, knowledge- and scientific-networking hampered growth and awareness of MAP research globally. The study recommends further research to strengthen evidence of MAP’s epidemiologic prevalence in ADs and proffer practical solution(s) for drug development and point-of-care diagnostics amongst other extended themes.

A Systematic Analysis of Research on Arcobacter: Public Health Implications from a Food–Environment Interphase Perspective

“…Also, published papers in the last 10 to 15 years in open access journals tend to have more citations than those published recently. It has also been shown that some authors are in the habit of citing themselves [ 50 ]. This practice can cause a false citation impact on the authors.…”

Neglected Facts on Mycobacterium Avium Subspecies Paratuberculosis and Type 1 Diabetes

“…Opportunistic infections caused by M. avium are among the most frequent in patients suffering from chronic respiratory infections and/or from acquired immunodeficiency syndrome [ 28 ]. However only MAP has been associated with a large number of autoimmune and inflammatory diseases and investigations all over the world are under way [ 29 ].…”

Warm, Sweetened Milk at the Twilight of Immunity - Alzheimer’s Disease - Inflammaging, Insulin Resistance, M. paratuberculosis and Immunosenescence

“…paratuberculosis (MAP). MAP has been killing livestock, contaminating food products and has been associated with human inflammatory and autoimmune diseases at a steadily increasing global rate for 100 years (13)(14)(15). Moreover, MAP can contribute to cellular and metabolic invariant features of AD; namely dysfunctional autophagy and insulin resistance (Figure 1).…”

“…Though the link of MAP zoonosis to Crohn's disease has been controversial for over one hundred years (13), validation of this association has come from studies showing Crohn's disease resolution with anti-mycobacterial therapy targeted against MAP (72)(73)(74)(75). Moreover, MAP is now linked to an increasing list of inflammatory and autoimmune diseases (13,76). To date, MAP has been causally associated with granulomatous diseases: Crohn's (77), sarcoidosis (78,79) and Blau syndrome (80).…”